From the Research
The recommended dosage for Imbruvica (Ibrutinib) is 420 mg orally once daily, as indicated by the most recent and highest quality studies 1. When considering the treatment of patients with certain types of cancer, such as mantle cell lymphoma or chronic lymphocytic leukemia, Imbruvica is often prescribed.
- The dosage may vary based on individual needs and the specific formulation.
- Imbruvica works by inhibiting the Bruton's tyrosine kinase (BTK) enzyme, which plays a crucial role in the signaling pathways that regulate cell growth and survival.
- It's essential to take Imbruvica consistently at the same time each day to maintain steady blood levels.
- The treatment duration typically continues until disease progression or unacceptable toxicity, and patients should be monitored regularly for adverse events.
- Common side effects of Imbruvica include diarrhea, fatigue, and nausea, and patients should be advised to report any severe or persistent side effects to their healthcare provider.
- As with any medication, it's crucial to consult with a healthcare provider before starting Imbruvica, as they can determine the appropriate dosage and treatment plan based on the patient's specific condition, age, and health status.
- Studies have shown that Imbruvica can significantly improve progression-free survival and overall survival in patients with certain types of cancer, making it a valuable treatment option 2, 1.